亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

SABR波动模型 医学 护理标准 缓和医疗 打开标签 离格 放射治疗 放射外科 随机对照试验 外科 护理部 随机波动 波动性(金融) 金融经济学 经济
作者
David A. Palma,Robert Olson,Stephen Harrow,Stewart Gaede,Alexander V. Louie,Cornelis J.A. Haasbeek,Liam Mulroy,Michael Lock,George Rodrigues,Brian Yaremko,Devin Schellenberg,Belal Ahmad,Gwendolyn H.M.J. Griffioen,Sashendra Senthi,Anand Swaminath,Neil Kopek,Mitchell Liu,Karen Moore,Suzanne Currie,Glenn Bauman
出处
期刊:The Lancet [Elsevier BV]
卷期号:393 (10185): 2051-2058 被引量:1869
标识
DOI:10.1016/s0140-6736(18)32487-5
摘要

Summary

Background

The oligometastatic paradigm suggests that some patients with a limited number of metastases might be cured if all lesions are eradicated. Evidence from randomised controlled trials to support this paradigm is scarce. We aimed to assess the effect of stereotactic ablative radiotherapy (SABR) on survival, oncological outcomes, toxicity, and quality of life in patients with a controlled primary tumour and one to five oligometastatic lesions.

Methods

This randomised, open-label phase 2 study was done at 10 hospitals in Canada, the Netherlands, Scotland, and Australia. Patients aged 18 or older with a controlled primary tumour and one to five metastatic lesions, Eastern Cooperative Oncology Group score of 0–1, and a life expectancy of at least 6 months were eligible. After stratifying by the number of metastases (1–3 vs 4–5), we randomly assigned patients (1:2) to receive either palliative standard of care treatments alone (control group), or standard of care plus SABR to all metastatic lesions (SABR group), using a computer-generated randomisation list with permuted blocks of nine. Neither patients nor physicians were masked to treatment allocation. The primary endpoint was overall survival. We used a randomised phase 2 screening design with a two-sided α of 0·20 (wherein p<0·20 designates a positive trial). All analyses were intention to treat. This study is registered with ClinicalTrials.gov, number NCT01446744.

Findings

99 patients were randomised between Feb 10, 2012, and Aug 30, 2016. Of 99 patients, 33 (33%) were assigned to the control group and 66 (67%) to the SABR group. Two (3%) patients in the SABR group did not receive allocated treatment and withdrew from the trial; two (6%) patients in the control group also withdrew from the trial. Median follow-up was 25 months (IQR 19–54) in the control group versus 26 months (23–37) in the SABR group. Median overall survival was 28 months (95% CI 19–33) in the control group versus 41 months (26–not reached) in the SABR group (hazard ratio 0·57, 95% CI 0·30–1·10; p=0·090). Adverse events of grade 2 or worse occurred in three (9%) of 33 controls and 19 (29%) of 66 patients in the SABR group (p=0·026), an absolute increase of 20% (95% CI 5–34). Treatment-related deaths occurred in three (4·5%) of 66 patients after SABR, compared with none in the control group.

Interpretation

SABR was associated with an improvement in overall survival, meeting the primary endpoint of this trial, but three (4·5%) of 66 patients in the SABR group had treatment-related death. Phase 3 trials are needed to conclusively show an overall survival benefit, and to determine the maximum number of metastatic lesions wherein SABR provides a benefit.

Funding

Ontario Institute for Cancer Research and London Regional Cancer Program Catalyst Grant.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
35766完成签到,获得积分10
4秒前
科研小白发布了新的文献求助10
4秒前
joejoe完成签到,获得积分10
11秒前
共享精神的应助被JY采纳,获得10
11秒前
科研通AI6.3的应助被卿亦佳人采纳,获得10
16秒前
stuhbnueducn完成签到,获得积分10
16秒前
小二郎的应助被科研通管家采纳,获得10
17秒前
17秒前
CodeCraft的应助被科研通管家采纳,获得10
18秒前
23202完成签到,获得积分10
19秒前
爆米花的应助被畅快的白枫采纳,获得10
20秒前
等待剑完成签到,获得积分10
21秒前
31483完成签到,获得积分10
22秒前
194完成签到,获得积分10
26秒前
idiot17完成签到,获得积分10
29秒前
如花完成签到 ,获得积分10
30秒前
34秒前
顺利的山柳完成签到,获得积分10
37秒前
共享精神的应助被科研小白采纳,获得10
39秒前
卿亦佳人发布了新的文献求助30
40秒前
corleeang完成签到 ,获得积分10
42秒前
mangle完成签到,获得积分10
43秒前
小张完成签到 ,获得积分10
44秒前
idiot17关注了科研通微信公众号
46秒前
乐研客完成签到,获得积分10
47秒前
48秒前
情怀的应助被独特幻然采纳,获得10
49秒前
高高笙完成签到,获得积分10
50秒前
50秒前
52秒前
朴实寻双发布了新的文献求助10
54秒前
美满惜雪发布了新的文献求助10
58秒前
朴实寻双完成签到,获得积分10
1分钟前
卿亦佳人发布了新的文献求助10
1分钟前
叆叇完成签到,获得积分10
1分钟前
肖坤完成签到,获得积分10
1分钟前
1分钟前
无语的小李完成签到,获得积分10
1分钟前
科研小白发布了新的文献求助10
1分钟前
科研小白完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184991
求助须知:如何正确求助?哪些是违规求助? 9573924
关于积分的说明 21833782
捐赠科研通 7782458
什么是DOI,文献DOI怎么找? 3434459
关于科研通互助平台的介绍 2558672
邀请新用户注册赠送积分活动 2481161